CY1122827T1 - Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους - Google Patents
Παροχη χοληστερυλεστερα σε στεροειδογονους ιστουςInfo
- Publication number
- CY1122827T1 CY1122827T1 CY20201100021T CY201100021T CY1122827T1 CY 1122827 T1 CY1122827 T1 CY 1122827T1 CY 20201100021 T CY20201100021 T CY 20201100021T CY 201100021 T CY201100021 T CY 201100021T CY 1122827 T1 CY1122827 T1 CY 1122827T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cholesteryl ester
- tissues
- steroidated
- delivery
- organ
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Αποκαλύπτονται συνθέσεις και μέθοδοι για την θεραπευτική αντιμετώπιση καταστάσεων που χαρακτηρίζονται από χαμηλή HDL-CE, η οποία μπορεί να οδηγήσει σε μειωμένη απελευθέρωση χοληστερυλεστέρα σε στεροειδογόνους ιστούς, μειώνοντας την ικανότητα του οργάνου να παράγει στεροειδή ειδικά κατά τη διάρκεια περιόδων ζήτησης, στρες ή συνδρόμου συστηματικής φλεγμονώδους απόκρισης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33190910P | 2010-05-06 | 2010-05-06 | |
PCT/US2011/035500 WO2011140429A1 (en) | 2010-05-06 | 2011-05-06 | Delivery of cholesteryl ester to steroidogenic tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122827T1 true CY1122827T1 (el) | 2021-05-05 |
Family
ID=44121177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100021T CY1122827T1 (el) | 2010-05-06 | 2020-01-09 | Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους |
Country Status (22)
Country | Link |
---|---|
US (2) | US20130045194A1 (el) |
EP (1) | EP2566505B1 (el) |
JP (1) | JP6174995B2 (el) |
CN (1) | CN103025348B (el) |
AU (1) | AU2011247985B2 (el) |
BR (1) | BR112012028462A2 (el) |
CA (1) | CA2797126C (el) |
CY (1) | CY1122827T1 (el) |
DK (1) | DK2566505T3 (el) |
ES (1) | ES2764733T3 (el) |
HR (1) | HRP20200008T1 (el) |
HU (1) | HUE047288T2 (el) |
LT (1) | LT2566505T (el) |
ME (1) | ME03682B (el) |
MX (1) | MX336872B (el) |
NZ (1) | NZ603453A (el) |
PL (1) | PL2566505T3 (el) |
PT (1) | PT2566505T (el) |
RS (1) | RS59867B1 (el) |
RU (1) | RU2012152320A (el) |
SI (1) | SI2566505T1 (el) |
WO (1) | WO2011140429A1 (el) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
KR20200085292A (ko) * | 2017-11-07 | 2020-07-14 | 알파코어 파마 엘엘씨 | 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0910343A1 (en) * | 1996-07-03 | 1999-04-28 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
US6498019B1 (en) * | 1997-04-11 | 2002-12-24 | Takeda Chemical Industries, Ltd. | Lecithin-cholesterol acyltransferase protein |
DE60222670T3 (de) * | 2001-07-27 | 2011-08-18 | N.V. Nutricia | Orale zusammesetzung zur vorbeugung oder behandlung von sepsis |
IL158554A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Mimetic lipids as dietary supplements |
BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
EP2037928B1 (en) | 2006-06-26 | 2012-01-11 | Amgen Inc. | Methods for treating atherosclerosis |
EP2489730B1 (en) * | 2007-07-26 | 2015-12-30 | Amgen, Inc | Modified lecithin-cholesterol acyltransferase enzymes |
WO2009124055A1 (en) * | 2008-03-31 | 2009-10-08 | University Of Chicago | Human apoa-i mutants |
AU2010259875B2 (en) * | 2009-06-12 | 2015-10-22 | Alphacore Pharma Llc | Use of LCAT for treating anemia and red blood cell dysfunction |
-
2011
- 2011-05-06 CA CA2797126A patent/CA2797126C/en not_active Expired - Fee Related
- 2011-05-06 US US13/695,919 patent/US20130045194A1/en not_active Abandoned
- 2011-05-06 ES ES11720265T patent/ES2764733T3/es active Active
- 2011-05-06 HU HUE11720265A patent/HUE047288T2/hu unknown
- 2011-05-06 AU AU2011247985A patent/AU2011247985B2/en not_active Ceased
- 2011-05-06 NZ NZ603453A patent/NZ603453A/en not_active IP Right Cessation
- 2011-05-06 RS RS20200004A patent/RS59867B1/sr unknown
- 2011-05-06 ME MEP-2020-1A patent/ME03682B/me unknown
- 2011-05-06 MX MX2012012711A patent/MX336872B/es active IP Right Grant
- 2011-05-06 BR BR112012028462A patent/BR112012028462A2/pt not_active IP Right Cessation
- 2011-05-06 CN CN201180022792.7A patent/CN103025348B/zh not_active Expired - Fee Related
- 2011-05-06 DK DK11720265.5T patent/DK2566505T3/da active
- 2011-05-06 RU RU2012152320/15A patent/RU2012152320A/ru not_active Application Discontinuation
- 2011-05-06 JP JP2013509288A patent/JP6174995B2/ja not_active Expired - Fee Related
- 2011-05-06 PL PL11720265T patent/PL2566505T3/pl unknown
- 2011-05-06 PT PT117202655T patent/PT2566505T/pt unknown
- 2011-05-06 LT LTEP11720265.5T patent/LT2566505T/lt unknown
- 2011-05-06 EP EP11720265.5A patent/EP2566505B1/en active Active
- 2011-05-06 SI SI201131832T patent/SI2566505T1/sl unknown
- 2011-05-06 WO PCT/US2011/035500 patent/WO2011140429A1/en active Application Filing
-
2014
- 2014-09-05 US US14/478,456 patent/US20150190479A1/en not_active Abandoned
-
2020
- 2020-01-03 HR HRP20200008TT patent/HRP20200008T1/hr unknown
- 2020-01-09 CY CY20201100021T patent/CY1122827T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2566505T1 (sl) | 2020-03-31 |
ME03682B (me) | 2021-01-20 |
AU2011247985B2 (en) | 2015-12-03 |
LT2566505T (lt) | 2020-02-10 |
CA2797126A1 (en) | 2011-11-10 |
JP2013528594A (ja) | 2013-07-11 |
US20130045194A1 (en) | 2013-02-21 |
PL2566505T3 (pl) | 2020-06-29 |
BR112012028462A2 (pt) | 2016-07-19 |
PT2566505T (pt) | 2020-01-15 |
DK2566505T3 (da) | 2020-01-20 |
CN103025348A (zh) | 2013-04-03 |
US20150190479A1 (en) | 2015-07-09 |
MX2012012711A (es) | 2012-11-21 |
ES2764733T3 (es) | 2020-06-04 |
EP2566505B1 (en) | 2019-10-16 |
WO2011140429A1 (en) | 2011-11-10 |
RU2012152320A (ru) | 2014-06-20 |
NZ603453A (en) | 2014-12-24 |
AU2011247985A1 (en) | 2012-11-29 |
HRP20200008T1 (hr) | 2020-03-20 |
RS59867B1 (sr) | 2020-03-31 |
CA2797126C (en) | 2020-06-02 |
CN103025348B (zh) | 2015-09-02 |
JP6174995B2 (ja) | 2017-08-02 |
EP2566505A1 (en) | 2013-03-13 |
HUE047288T2 (hu) | 2020-04-28 |
MX336872B (es) | 2016-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
EA201391602A1 (ru) | Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей | |
CY1119166T1 (el) | Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CR20170070A (es) | Composición, método y preparación del ácido biliar sintético | |
AU2016204344A1 (en) | Improved methods and compositions for wound healing | |
CY1125114T1 (el) | Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων | |
EA201290497A1 (ru) | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых | |
PH12014502445A1 (en) | Targeted modification of malate dehydrogenase | |
MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
BR112013003216A2 (pt) | composições sintéticas de ácido biliar e métodos | |
BR112013008881A2 (pt) | métodos e composições para tratamento de hemofilia b | |
WO2012020308A3 (en) | Pancreatic duct progenitor cells and microrna obtained therefrom for use in tissue regeneration | |
MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
EP2638159A4 (en) | COMPOSITIONS, KITS AND METHODS FOR TREATING CARDIOVASCULAR, IMMUNOLOGICAL AND INFLAMMATORY DISEASES | |
MX2020009699A (es) | Fenil acetato de l-ornitina y metodos para elaborar el mismo. | |
EP4234698A3 (en) | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies | |
CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
EP3634437A4 (en) | COMPOSITIONS AND PROCEDURES FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES | |
CA2868551C (en) | Methods and compositions for treating inflammation | |
EA201990438A1 (ru) | Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения | |
CY1122827T1 (el) | Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους | |
BR112014009376A2 (pt) | composições | |
CY1123202T1 (el) | Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης |